BioCardia takes a new and comprehensive approach to heart failure

We are developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases to improve the lives of patients from unmet medical needs.

Read More

Discover us

Financials & Filings

Review our corporate financial reports and SEC filings

Press Releases

Read about our latest company milestones

Clinical Trials

Complete Questionnaire to find out if you or a loved one qulifies for our CardiAMP Heart Failure Study

Product Pipeline

Learn about our product development programs and obtain an at-a-glance view of their current status

Products

Helix Biotherapeutic Delivery System

AVANCE Steerable Introducer

press releases

18 Sep
2024 BioCardia Regains Full Compliance with Nasdaq Listing Requirements
09 Sep
2024 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30 Aug
2024 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
29 Aug
2024 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
21 Aug
2024 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
13 Aug
2024 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS